AbbVie Reports the US FDA’s BLA Submission for TrenibotulinumtoxinE (TrenibotE) to Treat Glabellar Lines

Shots:The US FDA has received BLA for TrenibotE (botulinum neurotoxin serotype E) for the treatment of mod. to sev. glabellar linesBLA was supported by 2 pivotal P-III (M21-500 & M21-508) trials & an open-label P-III (M21-509) safety study assessing TrenibotE in over 2,100 ptsTrials met their 1 & 2EPs, with onset of…

ByRidhi RastogiApril 25, 2025

INSIGHTS+

Insights+: The US FDA New Drug Approvals in February 2024

Shots: PharmaShots has compiled a list of US FDA-approved drugs in the month of February 2024 The US FDA approved a total of 7 drugs including 6 new molecular entities and 1 biologic leading to the treatments for patients and advances in the healthcare industry The major highlighted drug was Takeda’s Eohilia (budesonide oral suspension) for treating eosinophilic…

BySenior EditorMarch 13, 2024

News

The US FDA Approves Hugel’s Letybo for the Treatment of Glabellar Lines

Shots: The US FDA has granted approval to the company’s Letybo for 50 and 100 units to treat moderate-to-severe glabellar lines in adults The approval was based on the data from three P-III completed studies that recruited more than 1,000 participants across the US and the EU The data from the clinical studies showed the…

ByDipanshu DixitFebruary 28, 2024

AbbVie Reports the US FDA’s BLA Submission for TrenibotulinumtoxinE (TrenibotE) to Treat Glabellar Lines

Insights+: The US FDA New Drug Approvals in February 2024

The US FDA Approves Hugel’s Letybo for the Treatment of Glabellar Lines

Contact US

OUR INFORMATION

FOLLW US

AbbVie Reports the US FDA’s BLA Submission for TrenibotulinumtoxinE (TrenibotE) to Treat Glabellar Lines

Insights+: The US FDA New Drug Approvals in February 2024

The US FDA Approves Hugel’s Letybo for the Treatment of Glabellar Lines

FOLLW US

Sign Up to Our Newsletter